Octapharma recalls Octagam lot in US
Octapharma has withdrawn one lot of its immune deficiency treatment Octagam after receiving reports of reports of allergic skin reactions in patients treated with the product.
The Swiss firm’s US unit – Octapharma USA – said the recall only affected one lot of Octagam Immune Globulin Intravenous (Human) 5% - number K551A8441 – that was made at its facility in Vienna, Austria.
“Although there have been no reports of serious injury at this time, Octapharma has determined, through consultation with the public health authorities at FDA, the most prudent course of action is to suspend further administration of this Octagam from this production lot.”
Octapharma did not respond to a request for comment.
